Uncategorized

Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.

Curasight A/S announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight’s uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.

Galderma announced it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid injectable designed for temporary augmentation of the chin region.2 Engineered to build and shape on bone with deep injection for a bone-mimicking effect,1,2,3,4† Restylane® SHAYPE™ will be available in Canada as of February 2024.

ANGLE plc is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal – “Current Issues in Molecular Biology” Special Issue: Advanced Solutions for Cancer Therapy.

Existen tesoros cósmicos que nos narran historias fascinantes sobre la evolución del sistema solar y la posibilidad de vida más allá de la Tierra. Uno de estos tesoros es el meteorito Allan Hills 84001, una roca marciana que ha cautivado la atención de cient&iacute …

En ese rincón del sistema solar conocido como el cinturón de Kuiper, Plutón se alza como un objeto celeste especialmente importante. Aunque alguna vez fue considerado el noveno planeta, su estatus ha cambiado, pero su magnetismo científico sigue inalterado. Los estudios s …

La naturaleza despliega ocasionalmente espectáculos que desafían nuestra comprensión y despiertan la curiosidad científica. Uno de estos fenómenos intrigantes es el “Fuego de San Telmo”, un baile etéreo de luz que ha fascinado a marineros y cient&i …

InnoCare announced that tafasitamab in combination with lenalidomide has been recently approved by the Medical Products Administration of Guangdong Province, under the early access program in Guangdong-Hong Kong-Macao Greater Bay Area, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.

Mirum Pharmaceuticals, Inc. announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units under Mirum’s 2020 Inducement Plan.

Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator’s choice of chemotherapy as a first-line treatment for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.